Research programme: multi-targeted cancer therapeutics - Curis

Drug Profile

Research programme: multi-targeted cancer therapeutics - Curis

Alternative Names: CU-0201; CU-201; CU-903; CU-906

Latest Information Update: 05 Nov 2012

Price : $50

At a glance

  • Originator Curis
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Cyclin-dependent kinase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase inhibitors; MTOR protein inhibitors; Src-Family kinase inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Oct 2012 Curis files an IND application with the US FDA for refractory lymphomas and multiple myeloma
  • 04 Apr 2012 Pharmacodynamics data from preclinical studies in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)
  • 16 Nov 2011 Pharmacodynamics data from preclinical trials in Cancer presented at the 23rd AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top